FDA Held Public Hearing on Psychedelic Therapeutics
Federal regulators heard from stakeholders on the future of psychedelic drug use during a September session.
Updated on Sept. 29, 2026 in Substance Abuse
Live Poll
Should federal drug policy prioritize emerging clinical research over long-standing historical restrictions on psychedelic drugs?
The U.S. Food and Drug Administration hosted a public hearing on September 14, 2026, to discuss the therapeutic potential of psychedelic drugs. The session gathered perspectives from various stakeholders to inform the agency's regulatory approach.
Why it matters
The hearing represents a significant step in gathering feedback on how to integrate psychedelic treatments into medical practice. Advocates are pushing for evidence-based frameworks to replace existing prohibition policies.
The hearing featured 80 selected speakers from a pool of hundreds of applicants. This follows the FDA's finalization of guidance for psychedelic drug clinical investigations issued in July 2026.
The players
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of human and veterinary drugs.
Students for Sensible Drug Policy
This international grassroots organization works to replace drug prohibition policies with evidence-based alternatives.
The details
The FDA hearing utilized both in-person and virtual formats to accommodate diverse stakeholder testimony. Simultaneously, advocates from Students for Sensible Drug Policy conducted an extensive education campaign, targeting over 200 congressional offices to influence national policy.
Timeline
April 2026: Executive Order 14401 directed federal agencies to accelerate psychedelic research.
July 2026: The FDA finalized guidance for psychedelic drug clinical investigations.
September 14, 2026: The FDA held a public hearing regarding psychedelic therapeutic use.
September 15, 2026: SSDP held 17 in-person meetings with congressional offices.
October 5, 2026: Deadline for the public to submit comments to the FDA.
The Big Picture
This story follows the momentum established by Executive Order 14401 to prioritize psychedelic research. The FDA hearing marks a shift toward regulatory formalization of substances previously excluded from therapeutic investigation.
The regulatory shift could eventually change available treatment options for patients suffering from conditions targeted by psychedelic therapy. Interested members of the public can still submit feedback to the agency until the October 5, 2026, deadline.
The takeaway
The FDA is currently synthesizing public feedback to determine its future approach to these therapies. Individuals interested in the outcome of these policy discussions should monitor federal announcements following the October comment deadline.
Further reading
For more context on how current drug regulations are evolving, visit the Substance Abuse section.
Live Poll
Should federal drug policy prioritize emerging clinical research over long-standing historical restrictions on psychedelic drugs?
